Therefore, our findings provide novel evidence that RPL8 may serve as a shared biomarker and a promising therapeutic target bridging inflammatory bowel disease and depression, although further mechanistic investigations are clearly warranted. This evidence concerns the gene RPL8 and major depressive disorder.